255 results on '"Buño I"'
Search Results
2. EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment
3. Personalized monitoring of circulating tumor DNA by a specific signature of trackable mutations after chimeric antigen receptor t‐cell therapy in non‐Hodgkin B cell lymphoma
4. La investigación biomédica hospitalaria a través de la satisfacción de los profesionales de un Instituto de Investigación Sanitaria
5. Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML
6. Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience
7. In vivo adhesion of malignant B cells to bone marrow microvasculature is regulated by α4β1 cytoplasmic-binding proteins
8. UGT2B17 minor histocompatibility mismatch and clinical outcome after HLA-identical sibling donor stem cell transplantation
9. PB2161: CHARACTERISTICS OF AGGRESSIVE B-CELL LYMPHOMAS WITH MYC REARRANGEMENT
10. P1423: CIRCULATING CELL-FREE DNA KINETICS MEASURED BY DIGITAL PCR IN LYMPHOMA PATIENTS UNDERGOING CD19-CAR-T THERAPY
11. P391: FLT3-ITD MEASUREMENT AT DIAGNOSIS AND FOR THE ASSESSMENT OF MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: CDNA VS. DNA
12. P1427: MONITORING CAR-T CELL IN B-CELL LYMPHOMA PATIENTS THROUGH SINGLE CHAIN VARIABLE FRAGMENT BY DIGITAL PCR
13. Additional file 1 of EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment
14. Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm
15. Early peripheral blood and T-cell chimerism dynamics after umbilical cord blood transplantation supported with haploidentical cells
16. Effect of mismatching for mHA UTA2-1 on clinical outcome after HLA-identical sibling donor allo-SCT
17. A variant in IRF3 impacts on the clinical outcome of AML patients submitted to Allo-SCT
18. ANALYSIS OF EZH2 MUTATIONS IN SOLID AND LIQUID BIOPSY AND ITS ROLE AS PREDICTIVE BIOMARKER FOR CHEMOTHERAPY IN PATIENTS WITH FOLLICULAR LYMPHOMA
19. RELAPSE CHARACTERIZATION IN DIFFUSE LARGE B CELL LYMPHOMA PATIENTS UNDERGOING COMMERCIAL CAR‐T CELL THERAPY: EXPERIENCE FROM A SINGLE CENTRE
20. CYCLOSPORINE IN COMBINATION WITH 3 VERSUS 4 DOSES OF METHOTREXATE FOR GRAFT VERSUS HOST DISEASE PROPHYLAXIS AFTER HLA-MATCHED ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE LEUKEMIA PATIENTS: PH-AB240
21. HAPLOIDENTICAL STEM CELL TRANSPLANTATION (HAPLO-HSCT) WITH HIGH DOSE CYLOPHOSPHAMIDE POST-TRANSPLANT (PT-CY) AS GVHD PROPHYLAXIS IN HIGH RISK HEMATOLOGIC MALIGNANCIES: MULTICENTRIC SPANISH EXPERIENCE: PH-P377
22. INFLUENCE OF KIR GENOTYPE ON SURVIVAL IN THE SETTING OF DUAL STEM CELL TRANSPLANTATION: PH-P076
23. Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation
24. A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms
25. Reliable quantification of hematopoietic chimerism after allogeneic transplantation for acute leukemia using amplification by real-time PCR of null alleles and insertion/deletion polymorphisms
26. Successful treatment of incipient graft rejection with donor leukocyte infusions, further proof of a graft versus host lymphohaemopoietic effect
27. Quantification of donor and recipient hemopoietic cells by real-time PCR of single nucleotide polymorphisms
28. Autologous stem cell transplantation in patients with acute myeloid leukaemia: results after long follow-up: P954
29. Dynamics of chimerism in activated leukocytes (CD25+) improves anticipation of acute GvHD after HLA-identical related allogeneic stem cell transplantation: P740
30. Mesenteric inflammatory veno-occlusive disease (MIVOD) after allogeneic peripheral blood stem cell transplantation (PBSCT)
31. Heterogeneous loss of the Y chromosome in leukocyte lineages of donor origin after stem cell transplantation
32. Reasons for which some stem cell transplant candidates are not finally transplanted. The experience of two Spanish SCT teams using an electronic tool to manage the SCT schedule
33. Successful treatment of graft rejection with immunosuppression withdrawal and/or donor leukocyte infusion after early diagnosis based on T-cell mixed chimerism
34. Cyclophosphamide + GCSF as mobilising schedule in multiple myeloma and malignant lymphoma patients: factors associated with mobilisation efficiency
35. The dynamics of chimerism evolution determines the differential outcome of various transplant settings
36. Lymphoma associated chromosomal abnormalities can easily be detected by FISH on tissue imprints. An underused diagnostic alternative
37. Heterogeneous loss of the Y chromosome in leukocyte lineages after SCT from a non-HLA-identical family donor
38. Efficacy of autologous stem cell transplant in aids-related lymphoma patients
39. Sau3A in situ digestion of human chromosome 3 pericentromeric heterochromatin. I. Differential digestion of α-satellite and satellite 1 DNA sequences
40. Diagnostic utility of fluorescence in situ hybridization in mantle-cell lymphoma
41. Fluorescence In Situ Hybridization Evaluation of Minimal Residual Disease on Stem-Cell Harvests
42. S1640 POLYMORPHISMS IN CYTOKINES, CHEMOKINES AND THEIR RECEPTORS GENES CONTRIBUTED TO CYTOMEGALOVIRUS REACTIVATION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
43. Monosomal karyotype in chronic lymphocytic leukemia: Association with clinical and biological features and potential prognostic significance
44. Chimerism Quantification after Sex-Matched BMT: How Probable Is It to Find Donor/Recipient Pairs with Distinguishable Cells?
45. Erratum: Quantification of donor and recipient hemopoietic cells by real-time PCR of single-nucleotide polymorphisms
46. Donor Cell MDS with Rare Complex Karyotype After Mismatch Alobmt for Ph+ALL
47. In vivo adhesion of malignant B cells to bone marrow microvasculature is regulated by α4β1 cytoplasmic-binding proteins
48. Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia
49. 65c - Donor Cell MDS with Rare Complex Karyotype After Mismatch Alobmt for Ph+ALL
50. 181 - SF3B1 Mutation in Low-Risk MDS: Impact of its Incorporation to the Updated 2016 Who Classification and Relationship with Ferric Overload
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.